In the latest session, Inari Medical Inc (NASDAQ: NARI) closed at $46.12 down -20.84% from its previous closing price of $58.26. In other words, the price has decreased by -$12.14 from its previous closing price. On the day, 6327233 shares were traded. NARI stock price reached its highest trading level at $51.00 during the session, while it also had its lowest trading level at $45.18.
Ratios:
For a deeper understanding of Inari Medical Inc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 22.89 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 90.46. For the most recent quarter (mrq), Quick Ratio is recorded 2.52 and its Current Ratio is at 3.09. In the meantime, Its Debt-to-Equity ratio is 0.07 whereas as Long-Term Debt/Eq ratio is at 0.07.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Piper Sandler on Mar-01-24, Downgraded its rating to Neutral and sets its target price to $55 from $85 previously.
On January 23, 2024, Needham started tracking the stock assigning a Buy rating and target price of $72.
On July 19, 2023, Robert W. Baird started tracking the stock assigning a Outperform rating and target price of $79.Robert W. Baird initiated its Outperform rating on July 19, 2023, with a $79 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Dec 15 when Hoffman William sold 25,000 shares for $65.08 per share. The transaction valued at 1,627,073 led to the insider holds 1,045,493 shares of the business.
Hill, Mitch C. sold 6,500 shares of NARI for $407,855 on Dec 12. The Chief Financial Officer now owns 170,230 shares after completing the transaction at $62.75 per share. On Nov 16, another insider, Hykes Andrew, who serves as the President and CEO of the company, sold 37,448 shares for $59.82 each. As a result, the insider received 2,240,277 and left with 434,817 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NARI now has a Market Capitalization of 3.36B and an Enterprise Value of 3.04B. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.38 while its Price-to-Book (P/B) ratio in mrq is 5.73. Its current Enterprise Value per Revenue stands at 6.47 whereas that against EBITDA is 253.27.
Stock Price History:
Over the past 52 weeks, NARI has reached a high of $71.85, while it has fallen to a 52-week low of $47.81. The 50-Day Moving Average of the stock is 59.82, while the 200-Day Moving Average is calculated to be 60.88.
Shares Statistics:
For the past three months, NARI has traded an average of 643.96K shares per day and 636.72k over the past ten days. A total of 57.76M shares are outstanding, with a floating share count of 49.16M. Insiders hold about 14.64% of the company’s shares, while institutions hold 85.91% stake in the company. Shares short for NARI as of Feb 15, 2024 were 4.97M with a Short Ratio of 7.73, compared to 4.41M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 8.64% and a Short% of Float of 10.86%.
Earnings Estimates
There are 10 different market analysts currently analyzing its stock. On average, analysts expect EPS of $0.01 for the current quarter, with a high estimate of $0.08 and a low estimate of -$0.06, while EPS last year was -$0.11. The consensus estimate for the next quarter is -$0.06, with high estimates of $0.05 and low estimates of -$0.13.
Analysts are recommending an EPS of between $0.13 and $0 for the fiscal current year, implying an average EPS of $0.06. EPS for the following year is -$0.09, with 11 analysts recommending between $0.56 and -$0.38.
Revenue Estimates
A total of 10 analysts believe the company’s revenue will be $132.09M this quarter.It ranges from a high estimate of $132.5M to a low estimate of $130.2M. As of the current estimate, Inari Medical Inc’s year-ago sales were $107.77M, an estimated increase of 22.60% from the year-ago figure. For the next quarter, 8 analysts are estimating revenue of $137.95M, an increase of 18.80% less than the figure of $22.60% in the same quarter last year. There is a high estimate of $143.3M for the next quarter, whereas the lowest estimate is $134.36M.
A total of 11 analysts have provided revenue estimates for NARI’s current fiscal year. The highest revenue estimate was $494M, while the lowest revenue estimate was $491.7M, resulting in an average revenue estimate of $493.63M. In the same quarter a year ago, actual revenue was $383.47M, up 28.70% from the average estimate. Based on 11 analysts’ estimates, the company’s revenue will be $588.34M in the next fiscal year. The high estimate is $601M and the low estimate is $569.8M. The average revenue growth estimate for next year is up 19.20% from the average revenue estimate for this year.
